Marion Merrell Dow

Marion Merrell Dow

Company type	Subsidiary
Industry	Pharmaceuticals
Founded	1950
Founder	Ewing Kauffman
Defunct	1996
Headquarters	Kansas City, Missouri , United States
Products	Cardizem, Carafate, Gaviscon, Seldane, Nicorette, Cepacol mouthwash
Number of employees	10,000 (1994)

Marion Merrell Dow and its antecedent, Marion Laboratories, were pharmaceutical firms based in the United States, with their headquarters located in Kansas City, Missouri from 1950 until 1996.

The company specialized in promoting medications that had been discovered but not previously marketed by other entities. Their portfolio included products such as Cardizem (used for arrhythmias and hypertension), Carafate (for treating ulcers), Gaviscon (an antacid), Seldane (an antihistamine later withdrawn), Nicorette (a gum to aid smoking cessation), and Cepacol mouthwash.

Operating from its main office at 9300 Ward Parkway, the enterprise also provided the foundation for founder Ewing Marion Kauffman to establish the Kansas City Royals baseball franchise.

Richardson-Merrell

The company's roots extend back to 1828 when William S. Merrell founded the Western Market Drug Store in Cincinnati, Ohio, which eventually expanded into pharmaceutical wholesale. Following his passing in 1880, his sons created the William S. Merrell Chemical Company.

During the 1930s, it merged with Lunsford Richardson’s firm to form Richardson-Merrell, recognized for products such as Vicks VapoRub. In 1958, Richardson-Merrell acquired Milton Antiseptic Ltd., a British company.

A significant milestone was achieved in 1956 when a team led by Frank Palopoli at William S. Merrell Chemical Company synthesized clomifene; the patent was secured in 1959. The company also developed chemicals including chlorotrianisene and ethamoxytriphetol.

Thalidomide

One of the most consequential episodes in Richardson-Merrell's history was its effort to introduce thalidomide into the U.S. market during the late 1950s and early 1960s under the name "Kevadon." Widely used in Europe as a sedative and antiemetic, it was frequently prescribed to pregnant women despite lacking formal approval for such use. On September 8, 1960, Richardson-Merrell submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) and distributed approximately 2.5 million tablets to around 1,200 physicians as part of a then-permitted premarketing strategy. Roughly 20,000 patients received the medication during this time frame.

FDA pharmacologist Frances Oldham Kelsey, who had recently joined the agency, consistently withheld approval due to inadequate safety evidence. After research connected thalidomide to severe birth defects affecting an estimated 10,000 children globally, Merrell retracted its application and recalled remaining supplies. In the United States, there were 17 reported cases of affected infants. For her steadfast regulatory oversight despite corporate pressure, Kelsey was honored with the President's Award for Distinguished Federal Civilian Service in 1962.

Merrell Dow Pharmaceuticals

In 1980, Dow Chemical purchased a controlling stake in Merrell's pharmaceutical division, creating Merrell Dow Pharmaceuticals. The original Richardson-Merrell entity evolved into Richardson-Vicks, Inc., which Procter & Gamble acquired in 1985, illustrating strategic realignments within both pharmaceutical and consumer goods sectors.

U.S. Supreme Court cases

Merrell Dow Pharmaceuticals played a central role in two landmark cases before the United States Supreme Court:

• Merrell Dow Pharmaceuticals Inc. v. Thompson (478 U.S. 804, 1986), addressing issues of original jurisdiction
• Daubert v. Merrell Dow Pharmaceuticals (509 U.S. 579, 1993), which established criteria for admitting scientific evidence under the Federal Rules of Evidence in federal court proceedings

Marion Merrell Dow

In 1989, Dow Chemical purchased a 67% ownership interest in Marion Laboratories, subsequently renaming the firm Marion Merrell Dow. This merger leveraged Marion’s extensive sales network alongside Merrell Dow’s strong research and development expertise, broadening the company’s product lineup to include items such as Seldane, Lorelco, Nicorette, and Cepacol. At that period, Marion Laboratories was outperforming all other pharmaceutical stocks by a factor of 2.5 and led NYSE-listed companies in both sales and profit per employee.

Dow’s initial bid was $38 per share, amounting to $2.2 billion for a 39% stake in Marion’s 150 million shares, with an option to raise its ownership to 67% by 1992. This transaction established the fifth-largest pharmaceutical firm in the United States by sales and resulted in 300 employees becoming millionaires. Although Dow held controlling interest, the company continued trading on the NYSE under Marion’s original ticker symbol "MKC."

Marion Laboratories

Founded in 1950 by entrepreneur Ewing Kauffman in Kansas City, Missouri, Marion Laboratories started with a modest $5,000 investment, initially selling calcium supplements derived from crushed oyster shells. Kauffman adopted his middle name for branding purposes to create an impression of a larger corporation.

The company expanded by implementing employee stock options and profit-sharing plans and concentrated on acquiring and reformulating existing products rather than conducting internal research. Officially incorporated in 1964, Marion marketed products such as Silvadene (a burn treatment), Ditropan (for bladder spasms), Nitro-Bid (chest pain relief), ARD and Bac-T-Screen (for bacterial identification), Culturette (used for streptococci detection), and ToxiLab (drug abuse screening).

By 1989, Marion Laboratories had achieved gross revenues of $930 million before its acquisition by Dow Chemical. By 1994, operating under the Marion Merrell Dow name, the company employed close to 10,000 individuals.

Hoechst Marion Roussel

In 1995, Germany-based Hoechst AG acquired Dow’s 71% stake in Marion Merrell Dow for $7.1 billion, forming what was then the world’s second-largest pharmaceutical company, trailing only Glaxo Wellcome and surpassing Merck & Company. Hoechst also purchased the remaining shares to gain full ownership. The newly formed entity, Hoechst Marion Roussel, retained its North American headquarters in Kansas City.

Sanofi

Subsequently, Hoechst merged with pharmaceutical and laboratory testing firm Aventis in 1999, which later became part of the global pharmaceutical leader Sanofi. In 2006, Sanofi divested the original Marion Labs facility in Kansas City to Cerner Corporation, signaling a strategic realignment of its worldwide operations. By August 2009, Sanofi announced it would close the remaining Kansas City plant due to reduced demand for its products, bringing an end to the legacy of Marion Laboratories.